Method of treating Parkinson's Disease with diarylmethylpiperazine compounds exhibiting delta receptor agonist activity
View Patent ↗Compositions and methods for treatment of Parkinson's disease to reduce the negative side effects of the disease by administering a therapeutically effective diarylmethylpiperazine compound which exhibits delta opioid receptor agonist activity, and optionally, mu receptor antagonist activity.
1. A method of treating Parkinson's disease in a subject experiencing same, the method comprising administering to said subject an effective amount of a therapeutic composition comprising a diarylmethylpiperazine compound of formula (I) or formula (II)
and pharmaceutically acceptable salts of the 4-((alpha-R)-alpha-((2S,5R)-2,5-Dimethyl-4-(3-fluorobenzyl)-1-piperazinyl)-3-hydroxybenzyl)-N,N-diethylbenzamide or 4-((alpha-R)-alpha-((2S,5R)-2,5-Dimethyl-4-(2-fluorobenzyl)-1-piperazinyl)-3-hydroxybenzyl)-N,N-diethylbenzamide compound; wherein the diarylmethylpiperazine compound of formula (I) or formula (II) exhibits delta opioid receptor agonist and mu opioid receptor antagonist activity.
2. The method of claim 1 , wherein said therapeutic composition is administered by an administration modality selected from the group consisting of oral, rectal, topical, sub-lingual, mucosal, nasal, ophthalmic, subcutaneous, intramuscular, intravenous, transdermal, spinal, intrathecal, intra-articular, intra-arterial, sub-arachnoid, bronchial, lymphatic, vaginal and intra-uterine administration.
3. The method of claim 2 , wherein said therapeutic composition further comprises another active Parkinson treating agent.
4. The method of claim 3 , wherein said another active Parkinson treating agent comprises an agent selected from the group consisting of apomorphine, benztropine mesylate, entacapone, selegiline hydrochloride, parmipexole dihydrochloride, carbidopa, levodopa, pergolide, ropinirole hydrochloride, amantadine hydrochloride, tolcapone.